Drug resistance is a well recognized problem in cancer therapy. Despite the current dogma that drug resistance is always an obstacle for treatment, here I show that it provides opportunities for selective protection of non-resistant cells with killing of drug-resistant cancer cells. According to the proposed 'twodrug' strategy, the first drug should be ineffective against a target drug-resistant cell (ie the drug is a substrate of MRP or Pgp pumps). In addition, it must be cytostatic but not cytotoxic. The second drug, which is applied in sequence, must be a cycle-dependent apoptotic drug to which the target cell is not cross-resistant. Thus, low doses of adriamycin, etoposide and actinomycin D, used as the first drugs, were cytostatic to parental HL60 cells. Therefore, these drugs precluded Bcl-2/Raf-1 phosphorylation, PARP cleavage and cell death which are otherwise induced by paclitaxel, a mitosis-selective apoptotic drug for HL60 cells. In contrast, HL60/ADR cells which express MRP, a transporter which pumps out the first drugs from a cell, were insensitive to the first drugs and therefore readily underwent apoptosis following the second drug. This strategy also allowed a selective killing of HL60/TX cells which express MDR-1, with the only difference being that the second drug, paclitaxel, was substituted for epothilones, non-Pgp substrates. Lack of protection by the first drug, a Pgp substrate, resulted in HL60/TX killing by the second drug, whereas parental HL-60 cells were fully protected. Therefore, drug resistant cells can be selectively killed by a combination of drugs not killing sensitive cells. Lack of toxicity against normal cells will be clinically translated in reduction of adverse side-effects of chemotherapy against drug-resistant malignancies.
Introduction
The statement 'the effect of anticancer therapy is limited by the development of drug resistance', as a common introduction to multidrug resistance in cancer, is consistent with tremendous attempts to reverse drug resistance. The most clear cut example is the multidrug resistance due to expression of the drug efflux pumps such as Pgp or MRP, because of the highly resistant phenotypes and available approaches to circumvent it. [1] [2] [3] For example, inhibitors of Pgp prevent efflux of chemotherapeutic drugs from a cell; and randomized clinical trials are underway. 4, 5 The ultimate goal of the conventional approach is complete reversal of multidrug resistance without toxicity of the reversal agent. However, even 'non-resistant' cancer cells are not easy targets because there is no specific molecular target for anticancer drugs. Anticancer drugs affect biological relevant molecules (ie DNA, microtubules, signal transduction kinases, oncoproteins) which are also essential for survival and/or proliferation of normal cells.
Ironically, drug resistance may provide such selectivity. One can envision that, following treatment with a cytostatic Correspondence: MV Blagosklonny; Fax: 301 402-0172 Received 5 July 1999; accepted 13 September 1999 drug, resistant cancer cells will continue to proliferate whereas non-resistant cells will cease proliferation. Then cells can be exposed to a second drug which kills only proliferating cells. This second drug should not be subject to resistance (in the present work, non-substrate of Pgp or MRP). Drug-resistant cells will then die, whereas non-resistant cells will be insensitive to the second drug due to cell cycle arrest by the first drug. Therefore, the second drug may selectively kill cells which are resistant to the first drug.
Is this scenario possible? Or are there too many requirements to be met by the drugs? I demonstrate that this situation is not only possible but can be achieved by using well-known chemotherapeutic drugs which are widely used in the treatment of cancer.
Materials and methods

Cell lines and reagents
HL60, a human leukemia cell line, was obtained from American Type Culture Collection (Manassas, VA, USA). HL60/ADR cells, a multidrug-resistant due to MRP clone of HL-60 cells, were described previously.
6 HL60/TX, a multidrug-resistant due to MDR1 clone of HL-60 cells, were obtained from Dr Bhalla (Emory University, Atlanta, GA, USA) and described previously. 7, 8 Vinblastine was obtained from the Development Therapeutics Program, NCI. Paclitaxel (Taxol), was a Bristol-Myers product. Epothilones A and B were provided by Dr F Lee (Bristol-Myers Squibb, Princeton, NJ, USA).
Immunoblot analysis
Cells were lysed and soluble proteins were harvested in TNES buffer (50 mM TrisHCl pH 7.5, 100 mM NaCl, 2 mM EDTA, 1 mM sodium orthovanadate, 1% (v/v) NP40) containing protease inhibitors (20 g/ml aprotinin, 20 g/ml leupeptin, 1 mM PMSF). Proteins were resolved with 7.5% SDS-PAGE for detection of PARP and Raf-1 or with 12.5% SDS-PAGE for detection of Bcl-2 as previously described. 9 Immunoblotting for Raf-1 and Bcl-2 was performed using the following antibodies: rabbit polyclonal anti-human Raf-1 (C12, Santa Cruz, Santa Cruz, CA, USA), and mouse monoclonal anti-human Bcl-2 (DAKO, Carpinteria, CA, USA) antibodies as previously described. 9 
MTT assay
15 000 cells were plated in 96-well flat bottom plates and then exposed to the pharmacological agents. At the indicated time (1-2 days), 20 l of 5 mg/ml MTT solution in PBS was added to each well for 4 h. After removal of the medium, 170 l of DMSO was added to each well to dissolve the formazan crystals. The absorbance at 540 nm was determined using a Biokinetics plate reader (Bio-Tek Instruments, Winooski, VT, USA). Triplicate wells were assayed for each condition and standard deviations were determined. 
DNA synthesis
Results
Cytostatic doses of adriamycin prevent paclitaxelinduced apoptosis in HL60 cells
Low doses of topoisomerase inhibitors, including adriamycin, etoposide, actinomycin D, can inhibit proliferation of parental HL60 cells without cell death. Microtubule-active drugs at doses which induce mitotic arrest cause apoptosis in HL60 cells. Early biochemical events are shown in Figure 1 . As expected, paclitaxel (PTX) induced Raf-1 and Bcl-2 hyperphosphorylation as an indicator of mitotic arrest and ensuing cell death. Cell death was preceded by the cleavage of Bcl-2 and PARP due to the activation of caspase-3, 10 which is characteristic of apoptosis. The cleavage of PARP was evidenced by disappearance of a 116 kDa band and the appearance of a truncated 85 kDa band ( Figure 1 ). Chemotherapy-induced cleavage of Bcl-2 protein is associated with apoptosis in myeloid leukemia cells. 9, 11 This was followed by cell death by 24-36 h, as evidenced by the inability to exclude trypan blue (data not shown) and lack of metabolism (MTT assay). Dramatic decrease of metabolically alive cells (MTT assay), in a short-term 1-2 day assay, correlates with cell killing rather than growth arrest, lane 2 (PTX) vs lane 3 (ADR) in Figure 1b .
Pretreatment with cytostatic doses of adriamycin (ADR) abrogated Raf-1 and Bcl-2 phosphorylation and significantly reduced PARP cleavage, to the extent that the decrease in fulllength PARP was not apparent (Figure 1a) . Accordingly, all HL60 cells were dead following exposure to PTX, whereas adriamycin-pretreated cells were alive (Figure 1b) . Optimal cytoprotection requires 12-16 h of pretreatment with adriamycin before an addition of paclitaxel.
In order to exert cytoprotection, concentrations of adriamycin should be sufficient to cause growth arrest but not be cytotoxic. Thus, doses of adriamycin below 5 ng/ml (which did not effectively block proliferation) did not protect against paclitaxel. On the other hand, although doses of adriamycin higher than 200 ng/ml can abrogate PTX effects, they induced cytotoxicity comparable with paclitaxel and therefore by no means could be beneficial (Figure 2 ).
Selective killing of HL/ADR cells
HL/ADR, a multidrug resistant clone of HL60 cells, expresses MRP and therefore resistant to adriamycin, actinomycin D,
Figure 1
Abrogation of the biochemical events associated death of HL60 cells. (a) HL60 cells were pretreated with 50 ng/ml adriamycin (ADR) and then 50 ng/ml paclitaxel (PTX) were added for 18 h. Bcl-2 and Raf-1 phosphorylation, as well as Bcl-2 and PARP cleavage, were evaluated by immunoblot as the markers of mitotic arrest and apoptosis. Note: as previously described, 9 the appearance of a 22 kDa Bcl-2 product following paclitaxel treatment could be only detected on grossly overexposed films. (b) Cells were treated as above, and MTT assay was performed after 2 days. and etoposide (VP16). 12 While conferring resistance to the Vinca compounds, MRP does not confer resistance to paclitaxel, 12 which, therefore, was chosen as a 'second' drug. As expected, both adriamycin and paclitaxel inhibited (Figure 3a) . Therefore, pretreatment with adriamycin did not abrogate paclitaxel-induced death of HL/ADR cells (Figure 3b,c) .
Thus, although HL/ADR cells are resistant to many drugs, they undergo apoptosis with the rational 'two-drug' approach whereas 'sensitive' parental cells were fully protected.
More examples of the first drugs
Success of the 'two-drug' strategy relied on the effective cytoprotection of 'sensitive' cells. This cytoprotection is due to cytostatic effect without cytotoxic one. Higher cytoprotection is shifted to lower doses of adriamycin with an increase of time (data not shown) underscoring that, while protective drug should not be cytotoxic, adriamycin at cytostatic doses is not completely free from toxicity.
Actinomycin D is more toxic than adriamycin, and cytoprotection was observed at doses 1-4 ng/ml (data not shown). VP16 demonstrated cytoprotective properties with a maximal effect at 400 ng/ml (Figure 4a ), whereas higher doses of VP16 were too cytotoxic. As with too low doses, too high doses of VP16 are ineffective. Importantly, HL/ADR cells were resistant to VP16, which result in lack of any protection of HL/ADR cells against paclitaxel cytotoxicity (Figure 4b) .
Emphasizing the importance of static vs toxic effects of the 'first' drug, neither UCN-01 nor lovastatin provided any protection because both drugs induced apoptosis at the same doses as they arrest growth of HL60 cells (data not shown).
Other microtubule-active drugs as the second agents in paclitaxel-resistant HL/TX cells
Using paclitaxel for selective killing HL/ADR cells was possible because these cells express MRP which confers resistance to the protective drugs but not to paclitaxel. However, a well characterized resistance mechanism in acute myeloid leukemia is mediated by MDR-1/Pgp, 13 which confers resistance to paclitaxel. Thus, HL/TX cells, a clone of HL60 cells selected for the paclitaxel resistance, expresses Pgp. 8 Although these cells are also resistant to the cytoprotective (first) drug, resistance to paclitaxel precludes any advantage ( Figure 5 ). However, like paclitaxel was effective in vincristine-resistant HL/ADR cells, another group of microtubule-active drugs can substitute for paclitaxel in paclitaxel-resistant HL/TX cells. In agreement with prior demonstrations that epothilones are effective against Pgp-expressing cells, 14 HL/TX cells were only marginally resistant to epothilones. Accordingly pretreatment with adriamycin, while protecting HL60 cells, did not protect either HL/ADR or HL/TX against epothilone A (data not shown) and epothilone B (Figure 6 ).
Discussion
The demonstration that drug resistance can be used for selective elimination of resistant leukemia cells reveals alternative strategies in cancer treatment. This approach requires at least two drugs acting in sequence. First, a merely cytostatic (not cytotoxic) drug to which a target cell is resistant. Opposite to that, a second drug to which the target cell is not cross-resistant is cytotoxic in a cell-cycle dependent manner. While the first drug protects normal cells, the second drug eliminates drug-resistant cells. This strategy is not limited to the resistance due to drug transporters (used here as a model) but is universal regardless of the particular mechanism of resistance to the first drug.
The drugs used in this study are currently employed in the treatment of cancer. Therefore, one does not need to test their effectiveness in animal models or humans. For example, administration of very low doses of adriamycin 16 h prior to paclitaxel can be suggested as a clinical trial for the treatment of the MRP-positive leukemia. The strategy is primary aimed not to increase the effectiveness of the drugs but to protect VP16 as a first drug in the 'two-drug' treatment. HL60 (a) or HL/ADR (b) cells were pretreated with indicated concentrations of (etoposide) VP16. After 16 h, medium or 100 ng/ml paclitaxel were added for an additional 24 h, and then MTT assay was performed. Results represent percent of control (untreated cells).
normal cells. This, in turn, can increase effectiveness of the treatment because a cure for cancer is limited by drug toxicity in a patient. Solving the dilemma between too low doses vs too high doses of the first drug, too high doses must be avoided because they might protect resistant cells.
As a disadvantage of the clinically available drugs, the first drugs were not designed for a mere cytostatic purpose. In cell culture, the cytostatic effects of these drugs (ie adriamycin) are hardly reversible. For example, although cytostatic doses of adriamycin protect parental cells from the second drug, clonogenic assay cannot be performed because non-proliferating cells cannot form colonies. This underscores that the identification of reversible pure cytostatic compounds is necessary.
What problems must be solved for success of this strategy? As we discussed, the second drug: (1) must induce rapid death; (2) of cycling cells; and (3) be active in target cells which are resistant to the first drugs. Current research efforts
Figure 5
The 'second drug' failure in HL/TX cells. Cells were pretreated with 60 ng/ml adriamycin for 16 h (closed symbols) or left without pretreatment (open symbols). Then cells were treated with paclitaxel for 36 h and MTT assay was performed. Results represent percent of control (untreated cells).
Figure 6
Epothilone B as a second drug. HL60, HL/ADR, or HL/TX cells were pretreated with 60 ng/ml adriamycin for 16 h and then were treated with epothilone B (Epo B) for 36 h and MTT assay was performed. Results represent percent of control (untreated cells).
are directed to the discovery of such drugs and some of them are already available. Thus, paclitaxel can serve as a 'second/eliminating drug' in HL/ADR cells, whereas epothilones are good substitutions in HL60/TX cells. Using the HL60 leukemia cell model, we certainly have an advantage that these cells readily undergo apoptosis after 16-24 h of exposure to microtubule-active drugs. Unfortunately, various cancer cells do not share this ability with leukemia cells. If the 'second' drugs induced slow cell death, the efficacy of the 'two-drug' approach may be diluted. Although much work still lies ahead, one can expect that the list of apoptotic and cycle-dependent drugs will expand.
Additional limitations include the expression of Pgp on some normal cells such as hematopoietic stem cells. 15 The two-drug strategy will not offer the protection to these particular normal cells if target cancer cells also express Pgp, although there would be no problems if mechanisms of resistance in cancer cells are different. This problem should not be overestimated because the same question could be readdressed to the conventional approach to reverse drug resistance by Pgp blockers: what about normal cells with Pgp?
Desirable properties of the 'first drugs' are not only opposite to the 'second drugs', but also opposes what is considered as 'good' apoptosis inducing anticancer drugs. [16] [17] [18] The first drug should be merely cytostatic to normal cells and completely ineffective against resistant cells due to the drug resistance. Although adriamycin or etoposide (VP16) were used here in in vitro experiments, a window of cytostatic but not toxic effect is narrow and, even at cytostatic doses, a long-term effect may decrease cell survival. Identification of merely cytostatic agents may be a cornerstone for the development of the 'two-drug' approach. While multidrug resistance provides numerous challenges, it also provides opportunities to achieve a high therapeutic index by maximizing the desired effect, and minimizing the undesired side-effects.
